DSIP

DSIP, or delta sleep-inducing peptide, is a small neuropeptide that has been studied for possible effects on sleep regulation, stress response, and neuroendocrine signaling. Interest in DSIP comes from older human and animal research suggesting that it may influence sleep architecture or sleep pressure, although the findings have not been consistently strong. A double-blind study in patients with chronic insomnia found modest improvements in some objective sleep measures, such as sleep efficiency and latency, but the authors concluded that the overall therapeutic effect was weak human study.

DSIP is thought to interact with sleep and stress-regulation pathways rather than act like a conventional sedative. Early human research examined whether intravenous DSIP could change sleep efficiency, sleep latency, and subjective tiredness. Some objective measures improved, but the overall results were mixed and did not show a large, reliable insomnia-treatment effect double-blind study. In a medspa or wellness context, DSIP is better framed as potential support for sleep quality, recovery, and nighttime regulation.

DSIP has a smaller modern human evidence base than commonly used sleep medications, so Careful clinician screening is necessary. The patient’s full medication list matters because sedating drugs, alcohol, sleep medications, and other neuroactive therapies can change both effectiveness and tolerability. Because Bowery offers DSIP as a capsule, the route differs from many of the older published studies, which is another reason not to promise the same effect or onset. Patients should report excessive sedation, dizziness, headache, unusual dreams, mood changes, or any worsening of sleep.

If DSIP produces a sleep-related effect, it may be noticed on the first few nights. Human sleep studies have evaluated effects over roughly 3–7 consecutive treatment nights, although results have been mixed. A practical assessment is therefore the first 1–2 weeks, tracking sleep onset, awakenings, total sleep time, and next-day alertness.

Bowery Clinic peptides are higher-strength and clinically dosed compared to most research facilities that use much lower concentrations. They are compounded by licensed 503A pharmacies with physician oversight and sterile quality standards, prioritizing real therapeutic outcomes over cheaper, unregulated research-grade products.

Yes. All pharmacies in our network are fully licensed in the states where they operate and comply with all state board of pharmacy regulations. Unlike many peptide clinics, we partner exclusively with FDA-registered U.S. pharmacies that undergo rigorous evaluation and compliance checks.

Every patient receives treatment plans developed and monitored by licensed providers. This includes safe titration of dosages and ongoing medical oversight tailored to individual needs.

Injections deliver the medication directly into your system. This makes the absorption more consistent and effective. Troches are small dissolvable lozenges that sit in your mouth until they melt, slowly releasing medication through the lining of your cheek or under your tongue.